Suppressing the pathological progression of liver fibrosis by inhibiting TGF-β1/SMAD and interleukin-13 (IL-13)/signal transducer and activator of transcription 6 (STAT6) pathwaysvia directly targeting semaphorin 4D[54]. The gene discussed is TGFB1; the disease is Hepatic fibrosis.